Exacerbation of Ischemic Heart Disease Following Abrupt Withdrawal —Hypersensitivity to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, myocardial infarction have occurred after abrupt discontinuation of such therapy. When discontinuing chronically administered nadolol, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of one to two weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, nadolol administration should be reinstituted promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue nadolol therapy abruptly even in patients treated only for hypertension.
CORZIDE (Nadolol and Bendroflumethiazide Tablets) for oral administration combines two antihypertensive agents: CORGARD® (nadolol), a nonselective beta-adrenergic blocking agent, and NATURETIN® (bendroflumethiazide), a thiazide diuretic-antihypertensive. Formulations: 40 mg and 80 mg nadolol per tablet combined with 5 mg bendroflumethiazide.
CORZIDE (Nadolol and Bendroflumethiazide Tablets) is indicated in the management of hypertension.
This fixed combination drug is not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient's needs, it may be more convenient than the separate components.
Published Studies Related to Corgard (Nadolol / Bendroflumethiazide)
Controlled trial of ligation plus nadolol versus nadolol alone for the prevention of first variceal bleeding. [2010.07]
CONCLUSION: The addition of ligation to nadolol may increase adverse events and did not enhance effectiveness in the prophylaxis of first variceal bleeding.
Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial. [2009.08]
CONCLUSIONS: Adding EBL to pharmacological treatment did not reduce recurrent bleeding, the need for rescue therapy, or mortality, and was associated with more adverse events. Furthermore, associating EBL to drug therapy did not reduce the high rebleeding risk of HVPG non-responders. ISRCTN26221020.
Clinical trial: a randomized controlled study on prevention of variceal rebleeding comparing nadolol + ligation vs. hepatic venous pressure gradient-guided pharmacological therapy. [2009.02.15]
BACKGROUND: Hepatic venous pressure gradient (HVPG) monitoring of therapy to prevent variceal rebleeding provides strong prognostic information. Treatment of nonresponders to beta-blockers +/- nitrates has not been clarified. AIM: To assess the value of HVPG-guided therapy using nadolol + prazosin in nonresponders to nadolol + isosorbide-5-mononitrate (ISMN) compared with a control group treated with nadolol + ligation... CONCLUSIONS: In patients treated to prevent variceal rebleeding, the association of nadolol and prazosin effectively rescued nonresponders to nadolol and ISMN, improving the haemodynamic response observed in controls receiving nadolol and endoscopic variceal ligation. Our results also suggest that ligation may rescue nonresponders.
Comparison of endoscopic variceal ligation and nadolol plus isosorbide-5-mononitrate in the prevention of first variceal bleeding in cirrhotic patients. [2006.10]
BACKGROUND: Both drug therapy and banding ligation are widely used in the prevention of first variceal bleeding. This study compared the efficacy and safety of band ligation vs. combination of beta-blocker and nitrate for the prevention of first bleeding in patients with cirrhosis and high-risk esophageal varices... CONCLUSION: Our preliminary results suggest that endoscopic variceal ligation is similar to the combination of nadolol plus ISMN with regard to effectiveness and safety in the prevention of first variceal bleeding in patients with cirrhosis.
Comparative study between nadolol and 5-isosorbide mononitrate vs. endoscopic band ligation plus sclerotherapy in the prevention of variceal rebleeding in cirrhotic patients: a randomized controlled trial. [2006.08.15]
BACKGROUND: After variceal bleeding, cirrhotic patients should receive secondary prophylaxis. AIM: To compare nadolol plus 5-isosorbide mononitrate (5-ISMN) with endoscopic band ligation. The end points were rebleeding, treatment failure and death... CONCLUSION: This trial suggests no superiority of endoscopic band ligation over nadolol plus 5-ISMN mononitrate for the prevention of rebleeding in cirrhotic patients.
Clinical Trials Related to Corgard (Nadolol / Bendroflumethiazide)
Nadolol for Proliferating Infantile Hemangiomas [Recruiting]
The purpose of this study is to explore the efficacy and safety of Nadolol in hemangiomas of
The secondary objective is to assess the feasibility of conducting a randomized controlled
trial comparing nadolol with corticosteroids and propranolol.
Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding [Recruiting]
Gastric variceal bleeding has a very high rebleeding rate even after endoscopic variceal
injection of cyanoacrylate (GVO) which is considered the first choice of endoscopic
treatment. Beta-blocker (BB) is effective to lower portal pressure. We hypothesized
combination of GVO and BB can further decrease the rebleeding rate.
Treatment for Prevention of Variceal Rebleeding Guided by the Hemodynamic Response [Recruiting]
This is a prospective trial of random distribution, open, parallel group, in which patients
with esophagic variceal bleeding will be randomized into two treatment groups, after
controlling acute bleeding. All patients received standard medical therapy with b-blockers
and endoscopic ligation (LEV) of esophageal varices.
The control group will be assigned to receive LEV + Nadolol + MNI. The experimental group
will be assigned to receive treatment according to the hemodynamic response.
All patients included in the experimental group received LEV and pharmacological treatment
nadolol alone or combined with MNI or Prazosin (PZ)
Oral Nadolol for the Treatment of Adults With Mild Asthma [Recruiting]
The purpose of this study is to confirm previous observations in asthmatics that chronic
nadolol treatment reduces asthmatic airway hyper-responsiveness.
Secondary Prophylaxis After Variceal Bleeding in Non-Responders [Completed]
Controlled and randomized study comparing combined treatment (nadolol and endoscopic
ligation) versus nadolol associated with isosorbide mononitrate or prazosin according to
hemodynamic response, in the prevention of esofagic verices rebleeding.
Reports of Suspected Corgard (Nadolol / Bendroflumethiazide) Side Effects
Muscle Spasms (7),
Injection Site Haemorrhage (6),
Abdominal Distension (6),
Breast Cancer (6), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 2 ratings/reviews, Corgard has an overall score of 9. The effectiveness score is 10 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
Corgard review by 51 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || high blood pressure|
|Dosage & duration:|| || 40 mg taken daily for the period of 25 years|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || Eliminated the irregular heart beat as well as the occasional heart racing in addition to controlling the blood pressure. Initially started taking while on birth control and having stress sytems of a racing heart beat.|
|Side effects:|| || Initially tired more than normal but tiredness subsided in a few days|
|Comments:|| || take daily in the morning|
Corgard review by 50 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || Moderate Side Effects|
|Condition / reason:|| || Mytral Valve Prolapse|
|Dosage & duration:|| || 20 mg daily taken 1 per day for the period of 20 years|
|Other conditions:|| || low blood pressure, skipped beats|
|Other drugs taken:|| || Quinadine Gluconate|
|Benefits:|| || The medication works very well in conjunction with the Quinadine Gluconate to help calm the extra heart beats. I started on the medication when I was 19 and am still on it today at age 50. I've tried other new drugs but always seem to come back to this tried and true one.|
|Side effects:|| || The only complaint I have is that Corgard tends to lower your blood sugar if you are prone to that anyway. If I increased my dosages to over 20mg daily, I would have many problems with low blood sugar, even to the point of passing out. I learned how to deal with it, but wish it was not a side effect.|
|Comments:|| || I was put on Corgard because of the Mytral Valve prolapse. I am very symptomatic. This greatly reduced the skipped beats. I take 1 tablet at night before going to bed.|
Page last updated: 2010-10-05